We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck’s (MRK - Free Report) second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024.
Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales declined 40% on a year-over-year basis to $1.33 billion in the first quarter of 2025. Gardasil declined 3% to $8.58 billion in 2024.
The lower demand in China has resulted in elevated channel inventory levels at Merck’s commercialization partner in China, Zhifei. As a result, Merck has decided to temporarily halt shipments of Gardasil in China from February through at least mid-year 2025 to allow Zhifei to move out existing inventory.
The economic headwinds in China led Merck to withdraw its previously issued long-term guidance of generating more than $11 billion in sales from Gardasil by 2030.
However, Gardasil sales are strong in almost every major region outside China, including the United States and Japan, driven by higher demand.
Merck expects global Gardasil growth, excluding China, to slow down going forward. Our model estimates for Gardasil suggest a CAGR decline of 6.4% over the next three years.
MRK's Other Vaccines & Competition in the Space
Merck markets several vaccines other than Gardasil. Besides Gardasil, it markets ProQuad/ M-M-R II/Varivax (measles, mumps, rubella and varicella virus vaccine, Vaxneuvance (pneumococcal 15-valent conjugate vaccine), RotaTeq (rotavirus vaccine), Pneumovax 23 (pneumococcal vaccine polyvalent) and its newest jab, Capvaxive (21-valent pneumococcal conjugate vaccine).
Earlier this month, the FDA approved its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV disease in newborns and infants. The product will be marketed under the brand name Enflonsia.
Enflonsia is expected to be launched in the United States ahead of the upcoming 2025-26 RSV season, while orders for the shots are expected to start in July.
However, upon its commercial launch, Enflonsia is likely to face stiff competition from AstraZeneca (AZN - Free Report) /Sanofi’s (SNY - Free Report) RSV antibody Beyfortus, which was also approved for a similar indication in 2023.
The AstraZeneca-Sanofi antibody, Beyfortus, achieved blockbuster status in its first full-year sales in 2024.
Besides antibodies, some other vaccines have been approved for preventing RSV in the United States. These include Pfizer’s (PFE - Free Report) Abrysvo, and GSK’s Arexvy.
Arexvy and Abrysvo are approved by the FDA for use in all individuals aged 60 and above. Arexvy is also approved for high-risk individuals aged 50-59, while Abrysvo is approved for high-risk adults aged 18-59 as well as for infants through maternal immunization.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 17.8% against the industry’s increase of 2.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.79 forward earnings, lower than 15.63 for the industry and its 5-year mean of 12.88.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.96 per share to $8.92, while the same for 2026 has decreased from $9.82 to $9.73 over the past 60 days.
Image: Bigstock
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Key Takeaways
Merck’s (MRK - Free Report) second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024.
Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales declined 40% on a year-over-year basis to $1.33 billion in the first quarter of 2025. Gardasil declined 3% to $8.58 billion in 2024.
The lower demand in China has resulted in elevated channel inventory levels at Merck’s commercialization partner in China, Zhifei. As a result, Merck has decided to temporarily halt shipments of Gardasil in China from February through at least mid-year 2025 to allow Zhifei to move out existing inventory.
The economic headwinds in China led Merck to withdraw its previously issued long-term guidance of generating more than $11 billion in sales from Gardasil by 2030.
However, Gardasil sales are strong in almost every major region outside China, including the United States and Japan, driven by higher demand.
Merck expects global Gardasil growth, excluding China, to slow down going forward. Our model estimates for Gardasil suggest a CAGR decline of 6.4% over the next three years.
MRK's Other Vaccines & Competition in the Space
Merck markets several vaccines other than Gardasil. Besides Gardasil, it markets ProQuad/ M-M-R II/Varivax (measles, mumps, rubella and varicella virus vaccine, Vaxneuvance (pneumococcal 15-valent conjugate vaccine), RotaTeq (rotavirus vaccine), Pneumovax 23 (pneumococcal vaccine polyvalent) and its newest jab, Capvaxive (21-valent pneumococcal conjugate vaccine).
Earlier this month, the FDA approved its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV disease in newborns and infants. The product will be marketed under the brand name Enflonsia.
Enflonsia is expected to be launched in the United States ahead of the upcoming 2025-26 RSV season, while orders for the shots are expected to start in July.
However, upon its commercial launch, Enflonsia is likely to face stiff competition from AstraZeneca (AZN - Free Report) /Sanofi’s (SNY - Free Report) RSV antibody Beyfortus, which was also approved for a similar indication in 2023.
The AstraZeneca-Sanofi antibody, Beyfortus, achieved blockbuster status in its first full-year sales in 2024.
Besides antibodies, some other vaccines have been approved for preventing RSV in the United States. These include Pfizer’s (PFE - Free Report) Abrysvo, and GSK’s Arexvy.
Arexvy and Abrysvo are approved by the FDA for use in all individuals aged 60 and above. Arexvy is also approved for high-risk individuals aged 50-59, while Abrysvo is approved for high-risk adults aged 18-59 as well as for infants through maternal immunization.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 17.8% against the industry’s increase of 2.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.79 forward earnings, lower than 15.63 for the industry and its 5-year mean of 12.88.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.96 per share to $8.92, while the same for 2026 has decreased from $9.82 to $9.73 over the past 60 days.
Image Source: Zacks Investment Research
Merck has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.